At Lykos Therapeutics, our mission is to transform the way mental health is treated. We aspire to challenge the status quo through the development of novel therapies and therapeutic approaches to treat mental health conditions. With 30+ years of experience researching psychedelic-assisted therapies, we remain focused on following rigorous science from which we can develop and commercialize novel treatment options. 

Founded in 2014 by the non-profit Multidisciplinary Association for Psychedelic Studies (“MAPS”), we are a for-profit public benefit corporation (“PBC”). As a PBC, we consider the impact of our decisions on society just as we think about financial implications. Everything we do is looked at through a public benefit lens. To learn more, visit us at www.lykospbc.com. 

Therapeutics

Life Sciences

Lykos Therapeutics (formerly MAPS PBC)

Michael Mullette

Dr. Berra Yazar-Klosinski

Andrew Septimus

Kacy Hutchison

Michelle Lacy

William Stewart

Blair Clark - Schoeb

Joy Sun Cooper

Berra Yazar - Klosinski

Allison Rosenthal

The Clinical Research and Development team at Lykos Therapeutics is dedicated to advancing the science of psychedelic-assisted therapies for mental health treatment. This interdisciplinary team conducts rigorous clinical trials, evaluates therapeutic effectiveness, and ensures adherence to study protocols, all aimed at developing innovative treatment options. By combining expertise in psychotherapy, research, and medical science, they drive the translation of groundbreaking research into practical therapies that address mental health challenges.

Clinical Research and Development

Financial and Administrative Support

Leadership Team

Clinical Research and Development

About

Team members

Other teams at Lykos Therapeutics (formerly MAPS PBC)

Financial and Administrative Support

Leadership Team